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Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L
tumours under oxic and hypoxic conditions
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Summary The acute toxicity, pharmacokinetics and hypoxic cytotoxicity of RSU-1069 were investigated
using the subcutaneous (sc) rat 9L tumour model. The pharmacokinetics were studied after i.p. injection of
RSU-1069 (20mgkg-' or 100mgkg-'). For both doses, the elimination of RSU-1069 followed first-order
kinetics in both plasma and unclamped tumours. After 100mgkg-', the peak plasma concentration of
RSU-1069 was 40 lgml-'; the elimination ti was 39.3± 11.lmin. After 20mgkg', the peak plasma
concentration was 3 pg ml-'; the elimination 4 was 47.8 ± 6.3 min. In unclamped tumours, the peak concen-
tration was 50jig g
-' with an elimination 4 of 36.1 ± 9.6 min for the 100 mg kg-' dose, and 4 tg g- with an
elimination 4 of 41.9 ± 6.1 min for the 20 mg kg-' dose. The tumour and plasma elimination half-times were
not significantly different (P> 0.2) for the two doses. Clamping the tumour 30 min after administration of
100mg kg-' of RSU-1069 decreased the tumour elimination t to 10.9 ± 1.4 min. After releasing the clamp,
RSU-1069 returned rapidly to the unclamped tumour concentration. The unclamped tumour/plasma ratio
reached a maximum of 4-6, then decreased to a constant value of about 2 for both doses, indicating that
RSU-1069 accumulates in these 9L tumours. RSU-1069 kills hypoxic sc 9L cells more efficiently than oxic
sc 9L cells; at a surviving fraction of 0.5, the SER was 4.8. For in vitro 9L cells, the SER was ; 50 when the
comparison was between those treated in 2.1% 02 and those treated in <7.5 x 10 3% 02; it was ; 100 when
the comparison was between those treated in 21% 02 and those treated in <7.5 x 10-3% 03. Tumours treated
with RSU-1069 and clamped for various times exhibited biphasic cell-kill kinetics; at 50mg kg-', little
additional cell kill was achieved after 40 min of clamping. Our data also indicate that RSU-1069 is 300-1000
fold more efficient than misonidazole or SR2508 for killing hypoxic sc9L tumour cells in situ.
The 2-nitroimidazoles, originally designed as electron affinic
radiosensitisers, have been reported to selectively kill hypoxic
cells (Adams et al., 1980). This hypoxic cytotoxicity appears
to be related to the anaerobic bioreductive metabolism of the
drugs that releases reactive cytotoxic metabolites (Clark et
al., 1980; Brown, 1982). By adding an alkylating group to the
side chain of a 2-nitroimidazole, Adams et al. (1984a,b)
postulated that a more efficient chemopotentiator and killer
of hypoxic cells could be made without the compound losing
its ability to sensitise hypoxic cells to ionising radiation.
RSU-1069 was one of the compounds synthesised to achieve
this goal.
RSU-1069 has an aziridine group attached via a side chain
to a 2-nitroimidazole. RSU-1069 is an effective radiosensitiser
and chemopotentiator in vitro and in vivo (Adams et al.,
1984a,b; Siemann et al., 1985; Ahmed et al., 1986). RSU-
1069 is toxic to both oxic and hypoxic cells in vitro; however,
it kills hypoxic cells far more efficiently than oxic cells
(Adams et al., 1984a,b; Whitmore & Gulyas, 1986; Stratford
et al., 1986; Olive et al., 1987, Keohane et al., 1990).
Although the ability to kill cells in vivo has been studied
(Adams et al., 1984a,b; Chaplin et al., 1986; Olive et al.,
1987; Cole et al., 1989; Siemann, 1989) the presence of both
oxic and hypoxic cells in these tumours has made it difficult to
determine if the relative efficiency of RSU-1069 for killing oxic
and hypoxic cells in vivo is similar to that reported in vitro.
In this report, we used the subcutaneous (sc) 9L tumour
model to study the relative ability of RSU-1069 to kill oxic
and hypoxic tumours cells in vivo. Sc 9L tumours appear to
contain no detectable radiobiologically hypoxic cells for
tumours that weigh up to 1 g (Wallen et al., 1980; Wheeler et
al., 1984). A reversible state of hypoxia can be produced in
these tumours by clamping the blood supply for up to 2 h
without killing any of the 9L tumour cells (Wheeler et al.,
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1984). Furthermore, the concentration of RSU-1069 as a
function of time after treatment can also be studied under
oxic (unclamped) and hypoxic (clamped) conditions using
this tumour model. Thus, the sc 9L tumour model allows one
to determine the effect of tumour oxygenation status on both
the pharmacokinetics and cytotoxicity of RSU-1069 in vivo.
Materials and methods
In vivo tumour system
The maintenance of 9L tumour cells in vitro and the proce-
dures for implanting 9L tumour cells subcutaneously in male
Fisher 344 rats (250-300 g) have been described elsewhere
(Wallen et al., 1980; Wheeler et al., 1984). Most of the
tumours used in these experiments, weighed 200-500 mg.
Drug storage andpreparation
The RSU-1069 used in these experiments was supplied by the
Drug Synthesis and Chemistry Branch of the Division of
Cancer Treatment at the National Cancer Institute. The pro-
perties and activity of the RSU-1069 were confirmed using a
recently synthesised lot, kindly supplied by Warner-Lambert
(Dr M. Suto). RSU-1069 was stored at -79'C and dissolved
at the appropriate concentration in sterile saline (0.85%
NaCI) immediately before use.
RSU-1069pharmacokinetics
Both a high (100mg kg-') and a low (20 mgkg-') dose of
RSU-1069 were used for the pharmacokinetic studies. The
procedure for clamping the tumours and the preparation of
plasma and tumour samples for analysis have been described
in detail elsewhere (Wong et al., 1989). In the clamped
experiments, RSU-1069 was administered 30 min before
clamping, and the tumours clamped for periods of up to 2 h.
The RSU-1069 concentration in the plasma and tumour
samples was measured as a function of time after drug
administration by an adaptation of the HPLC method des-
cribed by Walton & Workman (1988). The HPLC instru-
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mentation has been described in detail elsewhere (Wong et
al., 1989). RSU-1069 was isocratically eluted from a Spheri-
sorb phenyl column (Beckman Instruments). The mobile
phase consisted of 85% potassium phosphate buffer
(500 mM, pH 4.5) and 15% methanol at a constant flow rate
of I ml min'-. RSU-1069 was monitored at 320 nm, and the
lowest detectable quantity of RSU-1069 was 0.025 gAg ml-'.
The quantity of RSU-1069 in each sample was calculated by
comparison to a standard calibration curve.
Cell survival experiments
The in vivo to in vitro colony formation assay has been
described in detail elsewhere (Wallen et al., 1980; Wheeler et
al., 1984). In one set of experiments, RSU-1069 was admin-
istered at 10-50 mg kg-1, and the tumours clamped for 2 h.
In another set of experiments, 50 mg kg-' of RSU-1069 was
administered, and the tumours clamped from 10 min to 2 h.
As controls, rats bearing unclamped tumours were treated
with the same doses of RSU-1069. The colony formation
assay was always performed 18-24 h after the drug treat-
ment.
For the in vitro experiments, approximately 2 x 105 9L
cells were plated in the central area of glass petri dishes as
previously described (Koch, 1984) and incubated overnight at
37°C. Upon removal from the incubator, the dishes were
cooled to 4°C and the medium removed. After rinsing with
1 ml of drug-containing medium, 1 ml of drug-containing
medium was added. The dishes were then placed in leak-
proof aluminium chambers (Koch & Painter, 1975) which
were connected to a manifold and deoxygenated with a series
of gas exchanges that took about 30 min (Koch et al., 1984).
The oxygen concentration in the gas phase was monitored
using a polarographic oxygen sensor (Koch et al., 1984).
After deoxygenation, the chambers were rapidly brought to
37°C in a water bath and then placed in a 37°C incubator.
The chambers were gently shaken to prevent gradients of
oxygen, nutrients and RSU-1069. After the appropriate ex-
posure time, the cells were trypsinised and plated for colony
formation as previously described (Koch, 1984; Koch et al.,
1984).
Data analysis
A complete description of the statistical analysis for the
pharmacokinetics has been published (Wong et al., 1989).
Briefly, the data were weighted by the inverse variance and
analysed using the SAS nonlinear least-squares fitting rou-
tine. The exponential portions of these curves were compared
using a t-test for the equality of slopes generated by the SAS
program. All the in vivo to in vitro cell survival data are
presented as the geometric mean ± 1 s.e.m. and have been
corrected for cell yield as previously described (Rosenblum et
al., 1976).
Results
Pharmacokinetics
The plasma pharmacokinetics of RSU-1069 at 100mgkg-'
are shown in Figure la. The RSU-1069 peak plasma concen-
tration of -40 fgml-' occurred approximately 25 min after
i.p. injection. Elimination of RSU-1069 from plasma
appeared to follow first-order kinetics with a half-life (t4) of
39.3 ± 11.1 min. Clamping the tumour did not change the
elimination kinetics of RSU-1069 from plasma (t1
-41.4± 9.2 min, P> 0.9).
The distribution of RSU-1069 in unclamped and clamped
tumours is shown in Figure lb. In unclamped tumours,
RSU-1069 reached its peak concentration of 50p,ggg' in
30min. Elimination of RSU-1069 appeared to follow first-
order kinetics with a ti of 36.1 ± 9.6 min. Clamping the
tumour at 30 min decreased the elimination t1 of RSU-1069
to 10.9 ± 1.4 min (P<0.01). The drug was undetectable
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Figure 1 Pharmacokinetics of RSU-1069 after i.p. administra-
tion of 100 mgkg-' to rats bearing unclamped and clamped
sc 9L tumours. a, RSU-1069 concentration in plasma. b, RSU-
1069 concentration in tumour. Open circles represent rats whose
tumours were unclamped. Closed circles represent rats whose
tumours were clamped 30min after injection of RSU-1069. The
solid bar represents the period during which tumours were
clamped. The straight portion of each curve was fitted by linear
regression. Each data point represents the average of at least
three rats assayed individually in 2-3 independent experiments.
Error bars are ± 1 s.e.m; if not shown, they lie within the point.
The dashed lines in panel b were drawn because the RSU-1069
concentration in the clamped tumours at 150 min was undetect-
able.
beyond 120min after clamping. Upon release of the clamp,
the RSU-1069 concentration rapidly returned to the un-
clamped tumour level.
The peak plasma concentration of t 3fig ml-' was
reached about 10 min after injection of 20 mg kg-' of RSU-
1069 (data not shown). The peak plasma concentration after
a dose of 100 mg kg-' was about 13 times higher than that
found after a dose of 20 mg kg-'. The elimination of RSU-
1069 from the plasma after a dose of 20mgkg' followed
first-order kinetics with a t4 of 47.8 ± 6.3 min (data not
shown). This elimination t1 was not significantly different
(P>0.4) from the ti measured after a dose of 100 mg kg-'.
RSU-1069 reached a peak tumour concentration of
;4lgg-' 1Omin after a dose of 20mgkg' (data not
shown). The peak tumour concentration after a dose of
100 mg kg-' was also about 13 times higher than that found
after a dose of 20mgkg'. The elimination of RSU-1069
from sc 9L tumours also followed first-order kinetics with a t
of 41.9 ± 6.1 min (data not shown), which was not
significantly different (P> 0.2) from the t1 measured after a
dose of I00 mgkg-'.
Figure 2 shows the RSU-1069 data plotted as the tumour/
plasma ratio. In rats with unclamped tumours, the peak
tumour/plasma ratio exceeded four in about 45 min after a
100 mg kg-' dose and then decreased to two over the next
4 h (Figure 2a). The tumour/plasma ratio decreased to 0.1
about 90 min after clamping. After releasing the clamp, the
RSU-1069 concentration rapidly returned to the same ratio
as that found in the unclamped tumour. The variation of the
tumour/plasma ratio as a function of time after a dose of
20 mg kg-' was similar to that observed after a dose of
100 mg kg-' (Figure 2b). The ratio reached a maximum
value of six in 60 min and then decreased to a value of two
over the next 2 h.486 K.-H. WONG et al.
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Figure 2 RSU-1069 tumour/plasma ratio in rats bearing sc 9L
tumours. a, Tumour/plasma ratio after administration of
100mg kg-' of RSU-1069. b, Tumour/plasma ratio after admin-
istration of 20mg kg-' of RSU-1069. The open circles represent
rats whose tumours were unclamped. The closed circles represent
rats whose tumours were clamped 30 min after injection of RSU-
1069. The solid bar represents the period during which tumours
were clamped. The data were fitted by eye. Each data point
represents the average of at least 3 rats assayed individually in
2-3 independent experiments. Error bars are ± I s.e.m; if not
shown, they lie within the point.
RSU-1069 cytotoxicity
The ability of RSU-1069 to kill sc 9L tumour cells in vivo
under oxic and hypoxic conditions is shown in Figure 3a. No
cell kill was observed when the tumours were clamped for 2 h
without an RSU-1069 treatment (Wheeler et al., 1984). When
rats were treated with increasing doses of RSU-1069, a sub-
stantial difference in the kill was observed between sc 9L cells
from tumours left unclamped (oxic) and those from tumours
that were clamped for 2 h (hypoxic). At a dose of
50 mg kg', the surviving fraction was about 0.6 and 0.001
under oxic and hypoxic conditions, respectively (Figure 3a).
At a surviving fraction of 0.5, the sensitiser enhancement
ratio (SER) was 4.8. After a dose of 50 mg kg-1, a biphasic
cell kill curve was observed as a function of the extent of the
clamping period (Figure 3b). Most of the cell kill was
achieved in the first 40 min after clamping. This is consistent
with the 10 min elimination half-life measured for RSU-1069
in the clamped tumours (Figure lb). By comparison to our
previous work (Wong et al., 1989; 1990), RSU-1069 kills
hypoxic sc 9L tumours 300-1000 fold more efficiently than
either misonidazole (MISO) or SR-2508 (Table I).
The ability of RSU-1069 to kill 9L cells in vitro under oxic
and hypoxic conditions is shown in Figure 4. The SER in
vitro depended on the oxygen concentration. The SER was
t50 for 9L cells treated in an atmosphere of 2.1% 02
compared to those treated in an atmosphere of
<7.5 x 10-3% 02. For 9L cells treated in an atmosphere of
21% 02, the SER was -100.
Discussion
Pharmacokinetics
The high dose of RSU-1069 (100 mg kg-') was selected in
order to obtain an accurate measurement of the pharma-
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Figure 3 Surviving fraction of sc 9L tumour cells treated in vivo
with RSU-1069. a, Dose response curve for sc 9L tumours treated
with RSU-1069 under unclamped 0, and clamped (@) condi-
tions. b, Survival of sc 9L tumour cells as a function of clamping
time after administration of 50 mg kg-' of RSU-1069. The curves
were fitted by eye. Each data point represents the average of 4-6
tumours assayed individually in 2-3 independent experiments.
Error bars are ± I s.e.m; if not shown, they lie within the point.
Table I Surviving fraction for cells from clamped sc 9L tumours
treated with various 2-nitroimidazoles
AUC30.
Drug (mgml-' min-') Survivingfraction
MISO 52.6 0.95 ± 0.11
SR-2508 44.9 0.87 ± 0.17
RSU-1069 0.15 0.37+ 0.11
cokinetics in both unclamped and clamped tumours with
minimal systemic toxicity (LDm/30 ;k125mgkg-'). The low
dose of RSU-1069 (20 mg kg-') was selected to provide com-
parative pharmacokinetic data where the cell survival in un-
clamped and clamped tumours was ;t100% and ; 25%,
respectively (Figure 3a).
Both the low and high dose of RSU-1069 gave a similar
elimination tt in plasma and in tumours, but the peak con-
centrations differed by a factor of t13 instead of ; 5. These
results are in contrast to those observed in mice by Walton &
Workman (1988), where a 37% increase in the elimination ti
and a 2 fold difference in the volume of distribution was
observed after administration of i.p. doses of 50 and
100 mg kg-'. Although the exact reason(s) for these
differences are unknown, it is possible that the elimination of
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Figure 4 Surviving fraction of 9L cells treated in vitro with
RSU-1069. * 51LM RSU-1069, 7.5 x 10-3% 02 (extreme hy-
poxia); A 25011M RSU-1069, 2.1% 02; 0 5001IM RSU-1069,
21 % 02; The data points come from two independent
experiments and represent the average survival obtained by sum-
ming the colonies (always >450) in several dishes and dividing
by the untreated colony formation efficiency. All error bars
(± I s.e.m.) lie within the data points. The SER is estimated from
the ratio of the drug concentrations required to produced equal
cytotoxicity.
RSU-1069 (renal and/or hepatic) in rats may not have been
saturated at the 100 mg kg-' dose. If that were the case, no
differences in the elimination t1 between the two doses would
be expected. On the other hand, the distribution (absorption
or protein binding) could be saturated at the high dose of
100 mg kg-'; thereby, resulting in a higher than expected
peak concentration accompanied by a longer distribution
phase. The observation that it took 10 min to reach the peak
concentration at 20 mg kg-', and about 25 min to reach the
peak concentration at 100 mg kg-' supports this contention.
RSU-1069 accumulated in the unclamped sc 9L tumours,
as reflected by the high tumour/plasma ratio that peaked at
4-6 and remained at two for several hours after injection of
both the low and high dose (Figure 2). It has been reported
that the tumour/plasma ratio varies with tumour type. For
example, the KHT fibrosarcoma has an RSU-1069 tumour/
plasma ratio of 0.2-0.4 (Walton & Workman, 1988) while
the B16 and HX 118 melanomas have an RSU-1069 tumour/
plasma ratio of 3.7-4 (Deacon et al., 1986; Walling et al.,
1989). A correlation between the ability to accumulate RSU-
1069 and its relative antitumour activity has not been estab-
lished (Cole et al., 1989). Hence, this phenomenon will com-
plicate the interpretation of clinical pharmacokinetic and
cytotoxicity data.
The RSU-1069 elimination t1 after a 100mg kg-' dose
decreased significantly in clamped tumours ( 11 min) com-
pared to that observed in unclamped tumours (t 36 min).
Because these clamped sc 9L tumours are a closed system
with no influx or efflux of the drug, this decrease in the
elimination t1 probably results from the metabolic nitro-
reduction of RSU-1069 under hypoxic conditions. The elim-
ination of RSU-1069 from clamped sc 9L tumours was nearly
four times faster than the elimination tt of MISO or SR-2508
from clamped sc 9L tumours (Wong et al., 1989; 1990). This
difference in the elimination t, was not predicted because the
electron affinities of these three compounds are similar
(Adams et al., 1984a). Other metabolic pathways, such as
aziridine ring opening to yield RSU-1137 and aziridine ring
removal to yield RSU- 1111 (Walton & Workman, 1988),
may be responsible for some of the disappearance of the
parent compound.
Cell survival
In the cytotoxocity experiments, a fast and slow phase of cell
kill were observed when rats bearing sc 9L tumours were
administered a 50mgkg-' dose of RSU-1069 and the
tumours clamped for various periods of time (Figure 3b).
There are two possible explanations for the biphasic survival
curve. One explanation is that a resistant subpopulation of
9L cells exists in these tumours. This hypothesis is difficult to
test because the resistant subpopulation would comprise less
than 1% of the total cell population in these tumours (Figure
3b). The other explanation is that the generation of the
short-lived toxic metabolites is virtually complete after
40 min of clamping, so additional clamping time would not
be expected to increase the cytotoxicity further. This latter
hypothesis is supported by the rapid disappearance of RSU-
1069 in the clamped tumours (Figure lb).
After release of the clamp, the RSU-1069 concentration
returned to that in the unclamped tumour in about 60 min
(Figure lb). In the previous studies (Wong et al., 1989; 1990),
MISO and SR-2508 took approximately 45 and 90min to
return to the unclamped tumour level, respectively. This
delay suggested that the reduction of MISO and SR-2508
continued after the clamp was released. A similar mechanism
may be responsible for the slow return of RSU-1069 to the
unclamped tumour level in Figure lb.
Finally, this study demonstrated a differential cytotoxicity
of RSU-1069 under oxic and hypoxic conditions in vivo
(Figure 3a). Although systemic toxicity prevents assessment
of the in vivo SER at the low surviving fractions attainable in
vitro, the SER at a surviving fraction of 0.5 was about 4.8.
Recently, Bremner et al. (1990) observed a 3-4 fold increase
in the time required for KHT and RIF tumours to reach four
times their treatment size when the tumours were clamped
60 min after a dose of 80mg kg-' of RSU-1069. SERs
obtained in vitro have been reported to be as large at 100
(Stratford et al., 1986). In experiments where 9L cells were
treated in vitro with RSU-1069 in an atmosphere containing
21% 02, 2.1% 02 or <7.5 x 10-3% 02, the SER was 50
when the comparison was made between those treated in
2.1% 02 and those treated in <7.5 x 10-3% 02 (Figure 4).
This is similar to the results reported for other in vitro cells
(Stratford et al., 1986, Keohane et al., 1990). Although a
larger SER (t 100) was obtained when the results from the
21% 02 experiment were compared to the results from the
<7.5 x 10-% 02 experiment, the extracellular 02 concent-
ration in sc 9L tumours is probably best represented by the
concentration attained in the 2.1% 02 experiment. The large
difference between the SER obtained in vivo (4.8) and that
obtained in vitro (; 50) probably results from differences in
intracellular and extracellular factors (e.g. pH, nutrients,
non-protein thiol content, etc.) other than oxygen.
Clinical implications
In a phase I clinical trial (Horwich et al., 1986), nongeno-
toxic side-effects, such as emesis, limited the RSU-1069 dose
to less than 70mg m-2 (t 1.75 mg kg-'). In this clinical trial,
a peak plasma level of 2-4,tg ml-' of RSU-1069 was
achieved after a 70mgkg' dose. In our study, a plasma
level of 2-4pgmlm1 corresponds to a 10-20mgkg-' dose.
A 10-20 mg kg-' dose reduces the surviving fraction of
hypoxic sc 9L cells to only 0.5-0.25 (Figure 3a). In addition,
the radiosensitising enhancement ratio has been estimated to
be only 1.2 at this plasma level (Adams et al., 1984a).
Therefore, the clinical usefulness of RSU-1069 as a killer of
hypoxic cells or as a radiosensitiser is limited, unless the
drug-related side-effects can be overcome.
Because the aziridine ring in RSU-1069 can alkylate intra-
cellular macromolecules (Stratford et al., 1985) to cause oxic
cell cytotoxicity (Figure 3a), and metabolites of RSU-1069
that are formed under hypoxic conditions can potentiate the
cytotoxicity of a number of alkylating agents, RSU-1069 may
be an excellent potentiator of many alkylating agents (Adams
et al., 1984b; Siemann et al., 1985). In fact, RSU-1069 may
be the most efficient 2-nitroimidazole for killing hypoxic
sc 9L tumour cells (Table I) because it has both alkylating
and chemopotentiating properties (Adams et al., 1984a,b)
and is capable of self-potentiation when metabolised under
hypoxic conditions. Currently, we are investigating the use of
n488 K.-H. WONG et al.
small doses of RSU-1069 (<20 mg kg 1) to potentiate the
cytotoxic effects of a number of alkylating agents (e.g.
BCNU, CCNU, cyclophosphamide ifosfamide, darcarba-
zine). As a chemopotentiator, RSU-1069 might be clinically
useful at low doses that avoid the previously described severe
side-effects.
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